NKNicole Kogan

Nicole Kogan

*This is an algorithmically generated author record based on publicly available information.

Nicole Kogan has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Data from Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells

    by Fatma Aboulnasr, Ashton Krogman, Rondell P. Graham, Nathan W. Cummins, Anisha Misra, Enrique Garcia-Rivera, Jeff R. Anderson, Sekar Natesampillai, Nicole Kogan, Murali Aravamudan, et al.

    Supplementary tables and figures

  • Open Access

    Data from Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells

    by Fatma Aboulnasr, Ashton Krogman, Rondell P. Graham, Nathan W. Cummins, Anisha Misra, Enrique Garcia-Rivera, Jeff R. Anderson, Sekar Natesampillai, Nicole Kogan, Murali Aravamudan, et al.

    Purpose:TNF-related apoptosis inducing ligand (TRAIL) expression by immune cells contributes to antitumor immunity. A naturally occurring splice variant of TRAIL, called TRAILshort, antagonizes TRAIL-dependent cell killing. It is unknown whether tumor cells express TRAILshort and if it impacts antitumor immunity.Experimental Design:We used an unbiased informatics approach to identify TRAILshort expression in primary human cancers, and validated those results with IHC and ISH. TRAILshort-specific mAbs were used to determine the effect of TRAILshort on tumor cell sensitivity to TRAIL, and to immune effector cell dependent killing of autologous primary tumors.Results:As many as 40% of primary human tumors express TRAILshort by both RNA sequencing and IHC analysis. By ISH, TRAILshort expression is present in tumor cells and not bystander cells. TRAILshort inhibition enhances cancer cell lines sensitivity to TRAIL-dependent killing both in vitro and in immunodeficient xenograft mouse models. Immune effector cells isolated from patients with B-cell malignancies killed more autologous tumor cells in the presence compared with the absence of TRAILshort antibody (P < 0.05).Conclusions:These results identify TRAILshort in primary human malignancies, and suggest that TRAILshort blockade can augment the effector function of autologous immune effector cells.See related commentary by de Miguel and Pardo, p. 5546

  • Open Access

    Data from Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells

    by Fatma Aboulnasr, Ashton Krogman, Rondell P. Graham, Nathan W. Cummins, Anisha Misra, Enrique Garcia-Rivera, Jeff R. Anderson, Sekar Natesampillai, Nicole Kogan, Murali Aravamudan, et al.

    Purpose:TNF-related apoptosis inducing ligand (TRAIL) expression by immune cells contributes to antitumor immunity. A naturally occurring splice variant of TRAIL, called TRAILshort, antagonizes TRAIL-dependent cell killing. It is unknown whether tumor cells express TRAILshort and if it impacts antitumor immunity.Experimental Design:We used an unbiased informatics approach to identify TRAILshort expression in primary human cancers, and validated those results with IHC and ISH. TRAILshort-specific mAbs were used to determine the effect of TRAILshort on tumor cell sensitivity to TRAIL, and to immune effector cell dependent killing of autologous primary tumors.Results:As many as 40% of primary human tumors express TRAILshort by both RNA sequencing and IHC analysis. By ISH, TRAILshort expression is present in tumor cells and not bystander cells. TRAILshort inhibition enhances cancer cell lines sensitivity to TRAIL-dependent killing both in vitro and in immunodeficient xenograft mouse models. Immune effector cells isolated from patients with B-cell malignancies killed more autologous tumor cells in the presence compared with the absence of TRAILshort antibody (P < 0.05).Conclusions:These results identify TRAILshort in primary human malignancies, and suggest that TRAILshort blockade can augment the effector function of autologous immune effector cells.See related commentary by de Miguel and Pardo, p. 5546

  • Open Access

    Supplementary Data from Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells

    by Fatma Aboulnasr, Ashton Krogman, Rondell P. Graham, Nathan W. Cummins, Anisha Misra, Enrique Garcia-Rivera, Jeff R. Anderson, Sekar Natesampillai, Nicole Kogan, Murali Aravamudan, et al.

    Supplementary tables and figures

  • Open Access

    Leveraging Serosurveillance and Postmortem Surveillance to Quantify the Impact of Coronavirus Disease 2019 in Africa

    by Nicole E Kogan, Shae Gantt, David Swerdlow, Cécile Viboud, Muhammed Semakula, Marc Lipsitch, Mauricio Santillana

    Background: The coronavirus disease 2019 (COVID-19) pandemic has had a devastating impact on global health, the magnitude of which appears to differ intercontinentally: For example, reports suggest that 271 900 per million people have been infected in Europe versus 8800 per million people in Africa. While Africa is the second-largest continent by population, its reported COVID-19 cases comprise <3% of global cases. Although social and environmental explanations have been proposed to clarify this discrepancy, systematic underascertainment of infections may be equally responsible. Methods: We sought to quantify magnitudes of underascertainment in COVID-19's cumulative incidence in Africa. Using serosurveillance and postmortem surveillance, we constructed multiplicative factors estimating ratios of true infections to reported cases in Africa since March 2020. Results: Multiplicative factors derived from serology data (subset of 12 nations) suggested a range of COVID-19 reporting rates, from 1 in 2 infections reported in Cape Verde (July 2020) to 1 in 3795 infections reported in Malawi (June 2020). A similar set of multiplicative factors for all nations derived from postmortem data points toward the same conclusion: Reported COVID-19 cases are unrepresentative of true infections, suggesting that a key reason for low case burden in many African nations is significant underdetection and underreporting. Conclusions: While estimating the exact burden of COVID-19 is challenging, the multiplicative factors we present furnish incidence estimates reflecting likely-to-worst-case ranges of infection. Our results stress the need for expansive surveillance to allocate resources in areas experiencing discrepancies between reported cases, projected infections, and deaths.


  • Open Access

    Leveraging Serosurveillance and Postmortem Surveillance to Quantify the Impact of COVID-19 in Africa

    by Nicole E. Kogan, Shae Gantt, David Swerdlow, Cécile Viboud, Muhammed Semakula, Marc Lipsitch, Mauricio Santillana

    Background The COVID-19 pandemic has had a devastating impact on global health, the magnitude of which appears to differ intercontinentally: for example, reports suggest 271,900 per million people have been infected in Europe versus 8,800 per million people in Africa. While Africa is the second largest continent by population, its reported COVID-19 cases comprise Methods We seek to quantify magnitude of underascertainment in COVID-19’s cumulative incidence in Africa. Using serosurveillance and postmortem surveillance, we constructed multiplicative factors estimating ratios of true infections to reported cases in African nations since March 2020. Results Multiplicative factors derived from serology data – in a subset of 12 nations – suggested a range of COVID-19 reporting rates, from 1 in 630 infections reported in Kenya (May 2020) to 1 in 15 infections reported in South Africa (November 2021). The largest multiplicative factor, 3,795, corresponded to Malawi (June 2020), suggesting Conclusions While estimating COVID-19’s exact burden is challenging, the multiplicative factors we present provide incidence curves reflecting likely-to-worst-case ranges of infection. Our results stress the need for expansive surveillance to allocate resources in areas experiencing severe discrepancies between reported cases, projected infections, and deaths. Summary Here we present a range of estimates quantifying the extent of underascertainment of COVID-19 cumulative incidence in Africa. These estimates, constructed from serology and mortality data, suggest that systematic underdetection and underreporting may be contributing to the seemingly low burden of COVID-19 reported in Africa.

  • Innocent buffers reveal the intrinsic pH- and coverage-dependent kinetics of the hydrogen evolution reaction on noble metals

    by Onyu Jung, Megan N. Jackson, Ryan P. Bisbey, Nicole E. Kogan, Yogesh Surendranath


  • Open Access

    Characterizing features of outbreak duration for novel SARS-CoV-2 variants of concern

    by Alex D. Washburne, Nathaniel Hupert, Nicole Kogan, William Hanage, Mauricio Santillana

    Characterizing the dynamics of epidemic trajectories is critical to understanding the potential impacts of emerging outbreaks and to designing appropriate mitigation strategies. As the COVID-19 pandemic evolves, however, the emergence of SARS-CoV-2 variants of concern has complicated our ability to assess in real-time the potential effects of imminent outbreaks, such as those presently caused by the Omicron variant. Here, we report that SARS-CoV-2 outbreaks across regions exhibit strain-specific times from onset to peak, specifically for Delta and Omicron variants. Our findings may facilitate real-time identification of peak medical demand and may help fine-tune ongoing and future outbreak mitigation deployment efforts.


  • Top Cited Papers
    Open Access

    An early warning approach to monitor COVID-19 activity with multiple digital traces in near real time

    by Nicole E. Kogan, Leonardo Clemente, Parker Liautaud, Justin Kaashoek, Nicholas B. Link, Andre T. Nguyen, Fred S. Lu, Peter Huybers, Bernd Resch, Clemens Havas, et al.

    Multiple digital data streams forecast COVID-19 activity weeks before traditional epidemiological surveillance.


  • Open Access

    Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells

    by Fatma Aboulnasr, Ashton Krogman, Rondell P. Graham, Nathan W. Cummins, Anisha Misra, Enrique Garcia-Rivera, Jeff R. Anderson, Sekar Natesampillai, Nicole Kogan, Murali Aravamudan, et al.

    Purpose: TNF-related apoptosis inducing ligand (TRAIL) expression by immune cells contributes to antitumor immunity. A naturally occurring splice variant of TRAIL, called TRAILshort, antagonizes TRAIL-dependent cell killing. It is unknown whether tumor cells express TRAILshort and if it impacts antitumor immunity. Experimental Design: We used an unbiased informatics approach to identify TRAILshort expression in primary human cancers, and validated those results with IHC and ISH. TRAILshort-specific mAbs were used to determine the effect of TRAILshort on tumor cell sensitivity to TRAIL, and to immune effector cell dependent killing of autologous primary tumors. Results: As many as 40% of primary human tumors express TRAILshort by both RNA sequencing and IHC analysis. By ISH, TRAILshort expression is present in tumor cells and not bystander cells. TRAILshort inhibition enhances cancer cell lines sensitivity to TRAIL-dependent killing both in vitro and in immunodeficient xenograft mouse models. Immune effector cells isolated from patients with B-cell malignancies killed more autologous tumor cells in the presence compared with the absence of TRAILshort antibody (P < 0.05). Conclusions: These results identify TRAILshort in primary human malignancies, and suggest that TRAILshort blockade can augment the effector function of autologous immune effector cells. See related commentary by de Miguel and Pardo, p. 5546